Science & Health · Arbitrage#292

Indication-Nesting Coherence on Approval Markets

Drug markets nest: approval for a broad label implies approval, approval in a second indication implies approval in the first, and approval by June implies approval by December. Each of those is a strict subset relationship the prices must respect. Biotech markets are thin and are traded by people focused on the headline indication, so the narrower and broader legs regularly cross. You trade the pair rather than forecasting the science.

What you need to run it

Mapping of markets into nested families by indication, label breadth and deadline
Subset-relationship checks with alerting on violations
Capital patient enough to hold both legs through a long regulatory timeline

Where this applies

Markets on Polymarket where indication-nesting coherence on approval markets is the natural play:

Will the FDA approve the drug before December 2027?
Will the FDA approve the drug before June 2027?
Will the treatment be approved for the expanded indication?

Capabilities this demands

Custom code / APIDomain knowledgePatience

At a glance

CategoryArbitrage

MarketScience & Health

Requirements3

CapabilitiesCustom code / API, Domain knowledge, Patience

VenuePolymarket (CLOB, Polygon)

Build it

Related science & health strategies

This is documentation, not advice. Poly Research & Robotics publishes how these strategies work because the method should be checkable — not as a recommendation to trade them. See the full strategy database (297 strategies) or the data resources directory.